期刊
CLINICAL IMMUNOLOGY
卷 103, 期 1, 页码 13-21出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1006/clim.2001.5183
关键词
etanercept; rheumatoid arthritis; tumor necrosis factor; TNF; immune function; recombinant proteins
类别
资金
- NCRR NIH HHS [M01-RR00032] Funding Source: Medline
- NIAMS NIH HHS [5R01 AR 44384-03] Funding Source: Medline
Etanercept, a recombinant human tumor necrosis factor (TNF) inhibitor that binds both soluble and cell-bound TNF, has been shown to reduce disease activity and inhibit joint destruction when administered to patients with rheumatoid arthritis (RA). Because TNF receptors are found on many types of cells that modulate the immune response, we evaluated the general immune function of a subset of RA patients in a blinded clinical study. No significant differences were seen between patients treated with etanercept or placebo in the surface antigen phenotypes of peripheral blood leukocytes, T cell proliferative responses, neutrophil function, delayed-type hypersensitivity (DTH) reactions, serum immunoglobulin levels, or incidence of infections. Although this observational study was relatively small and could detect only major changes in immunological status, the stability of immune function over time in patients receiving etanercept corroborates the findings in clinical studies, which suggest that etanercept does not alter overall global immune function. (C) 2002 Elsevier Science (USA).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据